Fred is one of the Deputy Heads of Licensing and Ventures for Oxford University Innovation, leading the five-strong team focused on Digital Health and Bioinformatics.
Originally a biochemist, specialising in molecular kinetics and proteomics, Fred has worked as a research fellow in academia; provided commercial services and consulting to the pharma industry; co-founded a nanotech biosensor start-up; and worked as an applications specialist for GE Healthcare; before joining Oxford University Innovation four years ago. Since then he and his team have supported the commercialisation of an ever-growing portfolio of digital health and medtech innovations from the University and OUH NHS Trust, through a broad range of routes: from traditional technology licensing, partnering, and spinouts; through SaaS, open source and mixed-model licencing; to crowd-funding and social enterprise creation. Recognising the complexity in bringing digital health innovations to market, one of Fred’s strategic aims is to create a more connected digital health ecosystem in Oxford and the wider region. In this he works closely with the Oxford AHSN to establish a more efficient pathway for the adoption of digital health innovations. He is a strong advocate of the growing grassroots entrepreneurship encouraged and supported by organisations such as The Hill, Oxford Biodesign, and the Innovation Forum.

Carolyn is one of the Deputy Heads of Licensing and Ventures for Oxford University Innovation, with her team focusing on exploitation of technologies destined for the Pharma and Biotech industry.
Carolyn was originally an academic at Oxford University working in the field of immunology and has also worked as an analyst and in Corporate Finance at Ernst & Young and has held senior business development roles in big biotech (Chiron) and big pharma (Novartis). Since joining Oxford University innovation 8 years ago Carolyn has worked on commercialisation of a range of technologies and she has supported the foundation of 16 spin-out companies raising over £52M in seed financing. She is a member of the steering committee of LAB282 a £13M investment fund seeking to facilitate commercialisation of early stage drug discovery projects. Carolyn also sits on the boards of 5 Oxford spin-out companies and is a member of an Oxfordshire Women in Technology forum Techtonic that is seeking to promote entrepreneurship in collaboration with the Innovation Forum both inside the University and in the wider Oxford ecosystem.

Long and successful career as medtech business leader in large corporations, AIM listed companies and early stage ventures: CEO of Lombard Medical Technologies (2005 - 2009) and General Manager of Boston Scientific in UK (1999 - 2005). Currently board member of three emerging medtech companies, including OE.

Technology Director. Professor of Engineering Science and an expert in origami structures & minimally invasive medical devices. Gained funding from the Wellcome Trust Centre of Excellence to develop prototype medical devices.